%0 Journal Article
%A Courade, Jean-Philippe
%A Zetterberg, Henrik
%A Höglinger, Günter U
%A Dewachter, Ilse
%T The evolving landscape of Alzheimer's disease therapy: From Aβ to tau.
%J Cell
%V 188
%N 26
%@ 0092-8674
%C [Cambridge, Mass.]
%I Cell Press
%M DZNE-2025-01467
%P 7337 - 7354
%D 2025
%X A marked evolution in Alzheimer's disease (AD) therapy research is ongoing. In this perspective, we highlight emerging outcomes of tau-targeting approaches with disease-modifying potential evidenced by PET-based slowing of tau accumulation and early signs of cognitive benefit. We outline how decades of iterative amyloid β (Aβ)-trial refinement leading to the recent successes of approved anti-Aβ therapies have set the stage for accelerated optimization of next-generation trials. We summarize key learnings from first-generation tau immunotherapies and how these paved the way for early achievements in tau trials, while many challenges remain. Finally, we discuss the back-translation of clinical outcomes into fundamental insights on human tau pathobiology, and we outline challenges and future directions for AD therapy development including combination therapy and targets beyond Aβ/tau. Together, this provides a framework for next-generation AD and tau-therapy development toward increasingly efficient disease-halting interventions.
%K Alzheimer Disease: therapy
%K Alzheimer Disease: metabolism
%K Alzheimer Disease: drug therapy
%K Alzheimer Disease: pathology
%K Humans
%K tau Proteins: metabolism
%K tau Proteins: antagonists & inhibitors
%K Amyloid beta-Peptides: metabolism
%K Amyloid beta-Peptides: antagonists & inhibitors
%K Immunotherapy: methods
%K Animals
%K Clinical Trials as Topic
%K A(I)TN (Other)
%K ASO (Other)
%K AT(X)N (Other)
%K ATN (Other)
%K Abeta therapy (Other)
%K Alzheimer's disease (Other)
%K PET imaging (Other)
%K amyloid (Other)
%K anti-sense oligonucleotides (Other)
%K clinical trial (Other)
%K immunization (Other)
%K inflammation (Other)
%K neurodegeneration (Other)
%K next-generation therapies (Other)
%K tau (Other)
%K tau therapy (Other)
%K tauopathies (Other)
%K therapy development (Other)
%K trial (Other)
%K tau Proteins (NLM Chemicals)
%K Amyloid beta-Peptides (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41448139
%R 10.1016/j.cell.2025.11.033
%U https://pub.dzne.de/record/283060